ABSTRACT In a randomised, double blind crossover study the effect of high dose ipratropium bromide (200 pg three times daily given by metered dose inhaler for four weeks) on lung mucociliary clearance and on the wet weight and mean apparent viscosity of sputum was compared with that of placebo. Six smokers, six ex-smokers, and three non-smokers (12 men and three women, median age 60 years) were studied. Eight subjects had chronic obstructive lung disease (median FEV1 46% predicted) and seven had asthma (FEV1 70% predicted). Seven subjects produced sputum regularly, two of whom had asthma. Clearance of secretions was measured by an inhaled radioaerosol technique. The number of coughs and the wet weight, radioactive content, and mean apparent viscosity of sputum produced during the six hour observation period were recorded, as was the mean wet weight of sputum produced during the last two 24 hour periods ending each treatment.
The synthetic anticholinergic drug ipratropium bromide is an effective bronchodilator when given by metered dose inhaler 40 pg (that is, two puffs) four times daily, and this dosage for a week does not alter the clearance of secretions from the lungs. 1 2 Reports of the effects of higher doses of ipratropium bromide come from studies in which only single doses were given. Doses of up to 400 pg caused greater and longer lasting bronchodilatation,38 while doses of up to 200 pg did not affect lung mucociliary clearance.5 9 Bearing in mind the effect of atropine on secretions and lung clearance, 10 we have looked more closely for any deleterious effect of treatment with ipratropium bromide inhaled in high doses. We report here the effects on sputum production and apparent viscosity and on lung mucociliary clearance of four weeks' treatment with ipratropium bromide 200 pg three times daily given by metered dose inhaler to patients with airflow obstruction. 24 hours.14 The results were expressed as whole lung clearance, and as tracheobronchial clearance (whole lung clearance minus alveolar deposition) uncorrected and corrected for cough productive of sputum containing radioactivity. 5 The initial topographical distribution of the radioaerosol deposited in the lungs was monitored with a gamma camera (International General Electric) with a large field of view interfaced with a computer (Nodecrest). Posterior views were obtained to derive a penetration index for the 99"'Tc labelled particles (ratio of counts recorded over peripheral lung to those recorded over central lung). 16 This index estimates the degree of penetration into the lungs of this radioaerosol relative to that of labelled krypton gas, 8lmKr, that was subsequently inhaled.
STUDY PROTOCOL
The study was conducted in a double blind, crossover fashion. After baseline measurement of lung mucociliary clearance, the patients were allocated randomly to receive either ipratropium bromide-two puffs three times daily (100 Mg per pufl}-or a placebo that was identical in composition except for active drug-two puffs three times daily-for four weeks from identical metered dose inhalers. They were instructed to inhale in the recommended manner.'7 Randomisation was arranged so that half the patients should receive ipratropium bromide first; in fact, six received the active drug and nine placebo. The subjects continued to use the test inhalers for four weeks and while their mucociliary clearance was being measured after inhaling radioaerosol, but they stopped taking aminophylline and oral and inhaled 2 adrenoceptor agonist drugs during these six hours and for at least 12 hours beforehand, to avoid any influence on mucociliary function.' 8 Otherwise, since this study was not designed to assess the bronchodilator effect of high dose ipratropium bromide, the patients continued to take their regular treatment throughout the study, recording the number of puffs taken daily from their usual f2 agonist inhaler during each four week treatment period. While having each treatment, the subjects also recorded on diary cards their daily assessment of breathlessness, cough, wheeze, and satisfactory sleep according to a four point scale. Smoking was not permitted for at least one hour before or during the six hour observation period. During this period the number of coughs was counted and any expectorated sputum collected, its wet weight and radioactive content were recorded, and its mean apparent viscosity was measured with a modified capillary viscometer (Moleculex). We also recorded the wet weight of sputum produced at the end of each treatment period and during the 24 hours immediately before and the 24 hours after inhalation of radioaerosol. The 24 hour sputum wet weight was taken as the mean of these two observations.
The subjects performed lung function tests at the end of each four week treatment period, immediately before they inhaled the radioaerosol for measurement of lung mucociliary clearance, and about two hours after inhaling the last dose of test medication.
All adverse effects occurring during the course of the study were noted. Table 3 shows the values for mean inspiratory flow, penetration index, and alveolar deposition of radioaerosol. The penetration index was higher after treatment with ipratropium bromide than with placebo (p = 0.01) and higher after placebo treatment than at baseline (p < 0.01), although alveolar deposition and mean inspiratory flow did not change significantly.
Comparison of the results obtained after treatment with placebo and with ipratropium bromide showed no significant difference in the amount of radioaerosol remaining in the lungs at any half hour interval up to six hours. No significant difference was detected whether the results were expressed as whole lung clearance or as tracheobronchial clearance uncorrected (figure) or corrected for productive cough, and no significant difference was evident when analysis was confined to the seven subjects who regularly produced sputum. In these seven subjects, two of whom were asthmatic, the number of coughs and the wet weight and mean apparent viscosity of sputum produced during the six hour observation period were all the same after ipratropium bromide as after placebo, as was the wet weight of sputum collected during 24 hours at the end of each treatment period (table 4) .
There was no significant difference between the baseline results and those obtained after use of the placebo inhaler for four weeks in respect of uncorrected (figure) or corrected tracheobronchial clearance, sputum wet weight, or mean apparent viscosity (table 4) .
There were no significant differences between the periods of treatment with placebo and with ipratropium bromide in the number of puffs subjects took daily from their f2 agonist inhalers or in the diary card scores for breathlessness, cough, wheeze, or satisfactory sleep.
There were isolated reports in both treatment periods of cough, sore throat, wheeze, less sputum, rhinitis, breathlessness, and tightness in the chest. Most patients guessed which was the active treatment from its taste, and two described this as unpleasant. One man who had mild difficulty passing urine reported that this became worse after using ipratropium bromide for three and a half weeks, but did not report this after he changed to placebo.
Eight patients were withdrawn from the study. Three patients did not comply with the instructions for taking the trial medication, two had exacerbations of asthma while taking placebo, and three were with- Mean tracheobronchial retention (uncorrectedfor sputum production) at half hourly intervals for 15patients for baseline run and after four weeks' treatment with placebo and ipratropium bromide. drawn while taking ipratropium bromide but for unconnected reasons.
Discussion
Ipratropium bromide is an effective bronchodilator in chronic obstructive lung disease and asthma, and its bronchodilator effect is increased and prolonged with doses up to 10 times greater than the standard dose of 40 pg. 3 -8 20 21 The drug appears to be free of systemic side effects even when given in doses of up to 500 pg to treat acute severe asthma. 22 Indeed, it came into use as a bronchodilator because it lacked the systemic anticholinergic effects of atropine.23
Nevertheless, concern has been expressed about the use of ipratropium bromide, on the grounds that it might increase sputum viscosity and so exacerbate mucus plugging, particularly in asthma. 24 The clearance of secretions from the airways is determined by the physical characteristics of the airways, by ciliary action, and by cough. 25 The clearance of lung secretions may be impaired if any of these determinants is altered.
Previous studies showed that smaller doses of ipratropium bromide caused little or no alteration in the volume or viscoelastic properties of sputum produced by patients diagnosed as having chronic bronchitis, though some probably had asthma. 2629 The results of the present study are consistent with these observations, but firm conclusions about the effect of high dose ipratropium bromide on sputum cannot be drawn because the number of subjects who produced sputum was small. In studies of isolated animal airways the drug showed only a mild depressant activity on ciliary beat frequency, which was not dose related. 30 Table 4 Number of coughs and wet weight and mean apparent viscosity of sputun produced during the six hour observation period, and mean 24 hour wet weight of sputum produced at the end of each four week treatment period 
